testosterone + follitropin alfa

The combination of **testosterone + follitropin alfa** (recombinant FSH) is a clinical protocol used in reproductive medicine, specifically for ovarian stimulation in women identified as "poor responders" undergoing in vitro fertilization (IVF). This protocol involves pretreatment with transdermal testosterone, a small molecule androgen, which is thought to enhance the expression of follicle-stimulating hormone receptors (FSHR) on granulosa cells, thereby increasing ovarian sensitivity to subsequent stimulation. Following this pretreatment, recombinant follicle-stimulating hormone (follitropin alfa) is administered to stimulate the development of multiple follicles. This specific combination was evaluated in a randomized clinical trial (NCT01291212) sponsored by the **Hospital Clinic of Barcelona** to determine if this regimen could improve IVF outcomes compared to protocols adding recombinant luteinizing hormone (LH).

Other names

testosterone + fshrtestosterone + recombinant follicle-stimulating hormonetestosterone + recombinant FSH